Vimarsana
Biggest News Aggregation in the World

Page 5 - Physical Function News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Physical Function. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Physical Function Today - Breaking & Trending Today

UCB Showcases Key Rheumatology Data at ACR Convergence 2021 - Vimarsana News

UCB Showcases Key Rheumatology Data at ACR Convergence 2021

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new data on its investigational IL-17A and IL-17F inhibitor, bimekizumab, and its TNF...

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results - Vimarsana News

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
State pumps money into Covid research - Vimarsana News

State pumps money into Covid research

THE STANDARD By Augustine Oduor | March 13th 2021 at 00:00:00 GMT +0300 Kenyatta University student project leader Fidel Makatia conducts a demonstration during the launch of a prototype ventilator in April last year. [Elvis Ogina, Standard] Only one private university and six public institutions of higher learning have had their Covid-19 research proposals approved by the Government for funding. The National Research Fund (NRF) approved research proposals from Jomo Kenyatta University of Agriculture and Technology (JKUAT), University of Nairobi (UoN), Egerton University, Pwani University, ...

Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis - Vimarsana News

Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis Axogen, Inc.February 18, 2021 GMT ALACHUA, Fla., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of pilot phase analysis for its REPOSE clinical study.  Analysis of the REPOSE study’s 15-subject single arm pilot phase demonstrated that subjects experienced a clinically si...

Source: apnews.com